BioVaxys Joins BARDA RRPV Vaccine Development Consortium

In a significant development, BioVaxys Technology Corp. of Vancouver has announced its inclusion in The Rapid Response Partnership Vehicle (RRPV). The company, known for its innovative immunotherapies, has joined a collaborative consortium comprising various biopharma firms, contractors, government bodies, and research institutions. This consortium aims to assist the US Government's Biomedical Advanced Research and Development Authority (BARDA) in expediting the development of medical countermeasures to tackle pandemic influenza, emerging infectious diseases, and other biological threats.

The RRPV serves as a versatile acquisition platform designed to streamline the comprehensive development of future medical countermeasures. This platform focuses on facilitating the rapid acquisition and development of medical countermeasures from the early stages through to advanced development, procurement, and commercialization. It also emphasizes fostering innovation and rigorous development of medical technologies to enhance national health security.

A major objective of the RRPV is to support specialized product development, particularly for vaccines and therapeutic solutions. The consortium members are invited to submit proposals for individual projects, which BARDA evaluates and authorizes. This process results in the issuance of specific project agreements with consortium members.

Complementing BARDA's existing solicitation and acquisition mechanisms, such as the Broad Agency Announcement (BAA), the RRPV expands the capacity for rapid partnerships with product developers. This includes fields of interest to BARDA, such as improved influenza vaccines and platform technologies that enable expedited vaccine development.

Kenneth Kovan, BioVaxys President and COO, expressed his satisfaction with joining the RRPV consortium, which includes prominent organizations such as AstraZeneca, Battelle, Deutsches Zentrum für Infektionsforschung e.V., Genentech, Ginkgo Bioworks, Novavax, and Leidos. Kovan emphasized the significant role BioVaxys' DPX technology could play in advancing BARDA's priority vaccine programs and highlighted the benefits of collaborating with renowned consortium members.

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company committed to enhancing patient outcomes through its innovative DPX™ immune-educating technology platform and its HapTenix© "neoantigen" tumor cell construct platform. These platforms are designed for treating cancers, infectious diseases, antigen desensitization, and other immunological disorders.

The company's DPX™ platform employs a distinctive mechanism of action to instruct the immune system, generating specific, robust, and lasting immune responses. Among BioVaxys' advanced clinical developments is maveropepimut-S (MVP-S), based on the DPX™ platform, currently in Phase II clinical trials for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a recognized cancer antigen, along with an innate immune activator and a universal CD4 T cell helper peptide. It has shown positive results in multiple cancer indications, demonstrating a targeted and sustainable anti-tumor immune response.

Additionally, BioVaxys is developing DPX™+SurMAGE, a dual-targeted immunotherapy that combines antigenic peptides for survivin and MAGE-A9 cancer proteins to elicit immune responses to both cancer antigens simultaneously. Other projects include DPX™-RSV for Respiratory Syncytial Virus, DPX-rPA for anthrax, DPX-flu for influenza, and BVX-0918, a personalized immunotherapeutic vaccine for late-stage ovarian cancer using the HapTenix© platform.

BioVaxys shares are traded on the CSE under the symbol "BIOV," on the Frankfurt Bourse under "5LB," and in the US on the OTCQB under "BVAXF."